Fidelity Investments Portfolio holdings
Fidelity Investments, founded in 1946 by Edward C. Johnson II and headquartered in Boston, Massachusetts, is one of the largest privately-held financial services firms in the world, managing hundreds of billions in assets. Known for its wide array of investment products, including mutual funds, retirement accounts, brokerage services, and wealth management, Fidelity caters to both individual investors and institutions with a reputation for strong customer service and innovative tools like its active trader platforms. The company pioneered direct-to-investor mutual fund sales, bypassing traditional brokers, and has since expanded into areas like cryptocurrency trading and commission-free stock trades. Still family-controlled by the Johnson family, Fidelity blends a legacy of traditional investing with a forward-looking approach to technology and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$51.4B |
| 2 |
Broadcom
AVGO
|
+$8.12B |
| 3 |
NVIDIA
NVDA
|
+$6.62B |
| 4 |
UnitedHealth
UNH
|
+$5.92B |
| 5 |
Apple
AAPL
|
+$5.12B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marvell Technology
MRVL
|
+$14.9B |
| 2 |
Meta Platforms (Facebook)
META
|
+$12.7B |
| 3 |
SNDK
Sandisk
SNDK
|
+$7.89B |
| 4 |
Netflix
NFLX
|
+$6.05B |
| 5 |
Coherent
COHR
|
+$4.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.62% |
| 2 | Industrials | 10.81% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 9.29% |
| 5 | Financials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OKLO
1926
Oklo
OKLO
$6.69B
| $14.8M | ﹤0.01% |
283,221
+83,548
| +42% | +$5.21M |
|
1927
Tandem Diabetes Care
TNDM
$1.13B
| $14.7M | ﹤0.01% |
976,432
+262,421
| +37% | +$4.58M |
|
1928
Commerce Bancshares
CBSH
$8.39B
| $14.7M | ﹤0.01% |
254,704
+200,578
| +371% | +$10.5M |
|
1929
Precigen
PGEN
$2.51B
| $14.7M | ﹤0.01% |
2,570,183
+571,587
| +29% | +$2.47M |
|
|
ESPR
1930
DELISTED
Esperion Therapeutics
ESPR
| $14.6M | ﹤0.01% |
4,612,705
+4,238,224
| +1,132% | +$11.9M |
|
1931
ThredUp
TDUP
$326M
| $14.6M | ﹤0.01% |
2,126,272
-936,732
| -31% | -$4.38M |
|
1932
First Commonwealth Financial
FCF
$2.17B
| $14.5M | ﹤0.01% |
714,621
+128,009
| +22% | +$2.42M |
|
1933
Supernus Pharmaceuticals
SUPN
$2.4B
| $14.4M | ﹤0.01% |
309,091
+99,721
| +48% | +$4.79M |
|
1934
Vanguard Health Care ETF
VHT
$19B
| $14.3M | ﹤0.01% |
47,916
+1,929
| +4% | +$536K |
|
1935
Amneal Pharmaceuticals
AMRX
$5.8B
| $14.3M | ﹤0.01% |
825,120
+33,110
| +4% | +$454K |
|
1936
Itron
ITRI
$4.04B
| $14.3M | ﹤0.01% |
164,884
-55,186
| -25% | -$4.71M |
|
1937
CVR Energy
CVI
$5.24B
| $14.2M | ﹤0.01% |
516,413
-164,636
| -24% | -$5.23M |
|
1938
iShares ESG Aware US Aggregate Bond ETF
EAGG
$5.01B
| $14.2M | ﹤0.01% |
298,887
+15,243
| +5% | +$722K |
|
1939
AtriCure
ATRC
$2.86B
| $14.2M | ﹤0.01% |
506,357
+169,543
| +50% | +$4.77M |
|
1940
Oceaneering
OII
$4.75B
| $14.2M | ﹤0.01% |
349,342
+3,810
| +1% | +$144K |
|
1941
Vicor
VICR
$8.48B
| $14.1M | ﹤0.01% |
37,254
-128,072
| -77% | -$35M |
|
1942
Avantis Responsible International Equity ETF
AVSD
$371M
| $14.1M | ﹤0.01% |
176,440
+16,716
| +10% | +$1.32M |
|
1943
Fidelity High Dividend ETF
FDVV
$10.4B
| $14.1M | ﹤0.01% |
233,218
+25,142
| +12% | +$1.5M |
|
1944
Adtran
ADTN
$577M
| $14.1M | ﹤0.01% |
1,011,195
+395,759
| +64% | +$6.18M |
|
1945
DoubleVerify
DV
$2.09B
| $14M | ﹤0.01% |
1,294,427
+910,821
| +237% | +$9.37M |
|
1946
Blackstone Secured Lending
BXSL
$5.78B
| $13.9M | ﹤0.01% |
588,115
+18,735
| +3% | +$447K |
|
1947
Cleveland-Cliffs
CLF
$6.73B
| $13.8M | ﹤0.01% |
1,474,168
+418,508
| +40% | +$4.6M |
|
1948
Enbridge
ENB
$106B
| $13.7M | ﹤0.01% |
252,417
+26,546
| +12% | +$1.46M |
|
1949
Home BancShares
HOMB
$6.04B
| $13.7M | ﹤0.01% |
478,534
-472,929
| -50% | -$12.8M |
|
1950
Chemed
CHE
$6.62B
| $13.6M | ﹤0.01% |
29,268
-765
| -3% | -$322K |
|
Similar funds
Fidelity Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Fidelity Investments held 5,773 positions worth $2.3T, up 21% from $1.9T the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Fidelity Investments's Q2 2026 filing shows 351 new, 2,921 increased, 1,859 reduced and 211 closed positions. Its largest new stake was SpaceX: 302,555,831 shares worth $51.7B. The largest sale was Marvell Technology, an estimated $14.9B.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 32% a quarter earlier, followed by Industrials and Communication Services.
- Fidelity Investments's largest Q2 2026 buy was SpaceX: 302,555,831 shares worth $51.7B.
- Fidelity Investments added most to Broadcom in Q2 2026, an estimated $8.12B increase.
- Fidelity Investments's biggest Q2 2026 reduction was Marvell Technology, cutting an estimated $14.9B.
- Fidelity Investments fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $272M.
- Fidelity Investments's ten largest holdings make up 34% of its $2.3T portfolio in Q2 2026.
- Fidelity Investments opened 351 new positions and closed 211 in Q2 2026.
- Fidelity Investments's portfolio value rose 21% quarter-over-quarter to $2.3T.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.